CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Latest Financial Results

Q2 2023

Quarter Ended Jun 30, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In November 2022, CohBar announced that it had initiated a process to explore and review a range of strategic alternatives.

IR Contacts


CohBar, Inc.
1455 Adams Drive
Suite 1308
Menlo Park, CA 94025
T: (650) 446-7888

Investor Relations

T: (650) 446-7888

Transfer Agent

TSX Trust Company
301 – 100 Adelaide St W
Toronto, ON M5H 4H1